ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 23.5 TWD -0.63% Market Closed
Market Cap: 18.6B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note

ScinoPharm Taiwan Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ScinoPharm Taiwan Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
ScinoPharm Taiwan Ltd
TWSE:1789
Interest Income Expense
NT$53.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Y
YungShin Global Holding Corp
TWSE:3705
Interest Income Expense
NT$284.3m
CAGR 3-Years
265%
CAGR 5-Years
44%
CAGR 10-Years
20%
Formosa Laboratories Inc
TWSE:4746
Interest Income Expense
-NT$826.3m
CAGR 3-Years
N/A
CAGR 5-Years
-63%
CAGR 10-Years
-60%
S
SCI Pharmtech Inc
TWSE:4119
Interest Income Expense
-NT$181k
CAGR 3-Years
84%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Lotus Pharmaceutical Co Ltd
TWSE:1795
Interest Income Expense
NT$506.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Standard Chem & Pharm Co Ltd
TWSE:1720
Interest Income Expense
NT$130.1m
CAGR 3-Years
N/A
CAGR 5-Years
27%
CAGR 10-Years
26%
No Stocks Found

ScinoPharm Taiwan Ltd
Glance View

Market Cap
18.6B TWD
Industry
Pharmaceuticals

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Intrinsic Value
16.51 TWD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is ScinoPharm Taiwan Ltd's Interest Income Expense?
Interest Income Expense
53.3m TWD

Based on the financial report for Jun 30, 2024, ScinoPharm Taiwan Ltd's Interest Income Expense amounts to 53.3m TWD.

What is ScinoPharm Taiwan Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
102%

Over the last year, the Interest Income Expense growth was 102%.

Back to Top